Court Square recaps J. Knipper and Co
Summary
Suppliers of Pharmaceutical Samples Management Services, Combined with Its Rapidly Growing Specialty Pharmacy and Third-Party Logistics Business is Poised for Continued Growth with Private Equity Capital and Retention of Knipper Leadership Team Court Square Appoints Michael Laferrera as New Chief Executive Officer of Knipper; Elevates Frank McNicholas to Chief Operating Officer, in Addition to His Chief Financial Officer Role LAKEWOOD, N.J., Oct. 02, 2019 (GLOBE NEWSWIRE) — J. Knipper and Company, Inc. (the “Company”), one of the largest suppliers of end-to-end pharmaceutical samples management services in the U.S., and Court Square Capital Partners (“Court Square”), a middle market private equity firm, today announced a recapitalization of the Company and its affiliate KnippeRx, an independent specialty pharmacy. “Today marks a new chapter in the Company’s dedication to being the nation’s most complete provider of integrated therapeutic services and solutions across the spectrum of patient care – from initiation to continuation of therapy – for manufacturers, patients, providers and payers.” The recapitalization of J. Knipper and Company and KnippeRx is designed to accelerate growth, enhance competitive positioning within the marketplace, and ensure the Company will continue to have a strong leadership team. The leadership team is focused on continuing to deliver excellent customer service to help improve patients’ lives and maintaining a strong culture and workplace for its employees. As a patient-centric focused pharmacy, KnippeRx provides personalized patient assistance that includes PAP and starter dispensing of specialty therapies, high-touch biologics, and other products requiring temperature control. Court Square invests in companies that have compelling growth potential within the business services, general industrial, healthcare, and technology and telecommunications sectors.